Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials

[21] Ferdinand KC(2021)Effect of continued weekly subcutaneous Semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the step 4 randomized CLINICAL trial JAMA 10 1788-126

[22] White WB(2022)Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial Lancet Diabetes Endocrinol 24 639-1192

[23] Calhoun DA(2022)Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial Diabetes Obes Metab 11 118-59

[24] Lonn EM(2014)Global epidemiology of atrial fibrillation Nat Rev Cardiol 21 117-837

[25] Sager PT(2022)The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study Cardiovasc Diabetol 18 1184-1584

[26] Sun F(2019)Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation Lancet Neurol 45 53-583

[27] Wu S(2022)GLP-1RAs for ischemic stroke prevention in patients with type 2 diabetes without established atherosclerotic cardiovascular disease Diabetes Care 11 819-575

[28] Guo S(2010)Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community Rev Endocr Metab Disord 17 1570-41.e8

[29] Yu K(2013)Pharmacology, physiology, and mechanisms of incretin hormone action Cell Metab 159 554-2198

[30] Yang Z(2018)GLP-1 Receptor expression within the human heart Endocrinology 37 567-378

[21] Ferdinand KC(2021)Effect of continued weekly subcutaneous Semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the step 4 randomized CLINICAL trial JAMA 10 1788-126

[22] White WB(2022)Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial Lancet Diabetes Endocrinol 24 639-1192

[23] Calhoun DA(2022)Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial Diabetes Obes Metab 11 118-59

[24] Lonn EM(2014)Global epidemiology of atrial fibrillation Nat Rev Cardiol 21 117-837

[25] Sager PT(2022)The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study Cardiovasc Diabetol 18 1184-1584

[26] Sun F(2019)Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation Lancet Neurol 45 53-583

[27] Wu S(2022)GLP-1RAs for ischemic stroke prevention in patients with type 2 diabetes without established atherosclerotic cardiovascular disease Diabetes Care 11 819-575

[28] Guo S(2010)Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community Rev Endocr Metab Disord 17 1570-41.e8

[29] Yu K(2013)Pharmacology, physiology, and mechanisms of incretin hormone action Cell Metab 159 554-2198

[30] Yang Z(2018)GLP-1 Receptor expression within the human heart Endocrinology 37 567-378